What is Mei Pharma Inc's earnings per share (EPS)?

Mei Pharma Inc (MEIP) reported diluted earnings per share of -$2.39 for fiscal year 2025. This represents a -189.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Mei Pharma Inc (MEIP) Financials

MEIP

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$15.9M -189.7% YoY

EPS (Diluted) -$2.39 -189.5% YoY

Free Cash Flow -$20.8M +58.7% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Mar 31, 2026 Reported May 13, 2026 Currency USD FYE June

Newest figures come from the 10-K for Q3 FY2026, filed May 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MEIP SEC filings page.

Mei Pharma Inc (MEIP) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MEIP FY2025 2026-08-30

FY2024 profitability came from sharp expense compression, while the operating model still consumed cash

In FY2024, net income of $17.8M coexisted with operating cash flow of -$50.5M; reported profitability did not translate into cash from operations. The $49.1M investing inflow nearly matched that operating cash outflow, indicating that cash movement relied on sources outside the core operating result.

Operating results improved from a -$36.8M loss in FY2023 to a $14.5M profit in FY2024, pointing to a cost-structure change more than a volume-led operating story. R&D fell to $16.6M from $52.5M, making lower development spending the clearest visible mechanism behind the turnaround.

Debt-to-equity fell to 0.3x and the current ratio was 4.9x in FY2024, describing a lightly leveraged balance sheet with substantial current-asset coverage. Total assets fell from $120.8M in FY2023 to $41.4M in FY2024, so the improved ratios partly reflect balance-sheet contraction, not solely stronger operations.

Financial Health Signals

Financial health score not available

Mei Pharma Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

11.69

Mei Pharma Inc scores 11.69, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($100.8M) relative to total liabilities ($1.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Mei Pharma Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Mei Pharma Inc reported a net loss of $15.9M while operations used $20.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$54K

YoY-73.3%

QoQ-10.0%

Mei Pharma Inc generated $54K in revenue in Q3 2026. This represents a decrease of 73.3% from the same quarter a year earlier. Against the prior quarter it is down 10.0%.

Net Income

-$23.7M

YoY-820.9%

QoQ+23.1%

Mei Pharma Inc reported -$23.7M in net income in Q3 2026. This represents a decrease of 820.9% from the same quarter a year earlier. Against the prior quarter it is up 23.1%.

EPS (Diluted)

-$0.66

QoQ+19.5%

Mei Pharma Inc earned -$0.66 per diluted share (EPS) in Q3 2026. Against the prior quarter it is up 19.5%.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt

$7.5M

YoY-63.1%

QoQ-13.9%

5Y CAGR-5.0%

10Y CAGR-6.2%

Mei Pharma Inc held $7.5M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

34M

QoQ-6.4%

5Y CAGR-21.3%

10Y CAGR0.0%

Mei Pharma Inc had 34M shares outstanding in Q3 2026. Against the prior quarter it is down 6.4%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity

-41.7%

YoY-28.5pp

QoQ-4.1pp

Mei Pharma Inc's ROE was -41.7% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 28.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.1 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$30K

YoY-91.9%

QoQ-34.8%

Mei Pharma Inc invested $30K in research and development in Q3 2026. This represents a decrease of 91.9% from the same quarter a year earlier. Against the prior quarter it is down 34.8%.

Share Buybacks

$1.8M

Mei Pharma Inc spent $1.8M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

Not reported for Q3 2026.

MEIP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MEIP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	$0-100.0%	$65.3M+33.8%	$48.8M+19.9%	$40.7M+17.0%	$34.8M+25.4%	$27.8M+464.7%	$4.9M+203.0%	$1.6M-93.0%	$23.2M	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	$0-100.0%	$1.4M-47.3%	$2.7M-37.3%	$4.3M+26.0%	$3.4M-32.3%	$5.0M	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	$40.7M+21.9%	$33.4M+33.1%	$25.1M+3747.4%	$652K+137.0%	-$1.8M-109.6%	$18.2M	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$3.9M-76.3%	$16.6M-68.4%	$52.5M-38.8%	$85.6M+23.4%	$69.4M+103.7%	$34.1M+5.5%	$32.3M+89.6%	$17.0M+135.4%	$7.2M-46.0%	$13.4M-43.7%	$23.8M+23.2%	$19.3M+217.7%	$6.1M+23.8%	$4.9M+132.4%	$2.1M
SG&A Expenses	N/A	$13.5M-41.9%	$23.3M-29.7%	$33.1M+8.5%	$30.5M+25.1%	$24.4M+46.0%	$16.7M+14.5%	$14.6M+49.1%	$9.8M+13.4%	$8.6M+13.5%	$7.6M-15.1%	$8.9M+13.3%	$7.9M+53.7%	$5.1M+47.7%	$3.5M-19.8%	$4.3M
Operating Income	N/A	-$17.5M-220.0%	$14.5M+139.6%	-$36.8M+51.3%	-$75.5M-24.9%	-$60.4M-135.1%	-$25.7M+44.4%	-$46.2M-61.8%	-$28.6M-1299.1%	$2.4M+111.4%	-$21.0M+35.9%	-$32.8M-20.4%	-$27.2M-142.6%	-$11.2M-33.7%	-$8.4M-30.1%	-$6.5M
EBITDA	N/A	-$17.1M-214.5%	$14.9M+141.0%	-$36.4M+51.6%	-$75.2M-25.0%	-$60.1M-135.0%	-$25.6M+44.6%	-$46.2M-61.8%	-$28.5M-1255.7%	$2.5M+111.8%	-$20.9M+36.0%	-$32.7M-20.3%	-$27.2M-143.2%	-$11.2M-33.4%	-$8.4M-30.2%	-$6.4M
Income Tax	N/A	$0	$0	$0	$0-100.0%	$8K+700.0%	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%	$1K0.0%	$1K
Net Income	N/A	-$15.9M-189.7%	$17.8M+155.6%	-$32.0M+40.7%	-$54.0M-31.7%	-$41.0M+13.1%	-$47.2M-180.5%	-$16.8M+58.0%	-$40.1M-1600.7%	$2.7M+112.8%	-$20.9M+36.2%	-$32.7M-20.4%	-$27.1M-142.7%	-$11.2M-48.7%	-$7.5M-10.9%	-$6.8M
EPS (Basic)	N/A	-$2.39-189.5%	$2.67+155.9%	-$4.78+45.4%	-$8.75-2264.9%	-$0.37+28.8%	-$0.52-116.7%	-$0.24+75.3%	-$0.97-1485.7%	$0.07+111.5%	-$0.61+47.4%	-$1.16	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$2.39-189.5%	$2.67+155.9%	-$4.78	-$9.99	-$0.60-15.4%	-$0.52	-$0.75	-$0.97-1485.7%	$0.07+111.5%	-$0.61+47.4%	-$1.16	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	7M0.0%	7M0.0%	7M	6M	114M+25.7%	91M	72M	41M+12.2%	37M+7.4%	34M+22.0%	28M	N/A	N/A	N/A	N/A

Metric	Q3'2610-K	Q2'2610-Q	Q1'2610-K	Q4'2510-K	Q3'25	Q2'25	Q1'25	Q4'2410-K
Revenue	$54K-73.3%	$60K-78.5%	N/A	N/A	$202K	$279K	$0-100.0%	N/A
R&D Expenses	$30K-91.9%	$46K-85.1%	$10K-99.7%	N/A	$369K-92.9%	$308K-92.1%	$3.2M-9.2%	N/A
SG&A Expenses	$2.7M+13.7%	$3.3M+5.2%	$3.1M-40.3%	N/A	$2.4M-47.8%	$3.1M-60.8%	$5.2M-20.5%	N/A
Operating Income	-$21.6M-679.0%	-$29.9M-765.5%	-$3.7M+55.2%	N/A	-$2.8M+71.8%	-$3.5M+71.1%	-$8.4M-115.1%	N/A
EBITDA	N/A	N/A	-$3.7M+53.2%	N/A	N/A	N/A	-$8.0M-114.4%	N/A
Net Income	-$23.7M-820.9%	-$30.8M-1050.5%	-$3.6M+54.6%	N/A	-$2.6M+71.8%	-$2.7M+75.8%	-$8.0M-114.2%	N/A
EPS (Basic)	-$0.66-69.2%	-$0.82-105.0%	-$0.12+90.0%	N/A	-$0.39+71.5%	-$0.40+75.9%	-$1.20-114.2%	N/A
EPS (Diluted)	-$0.66	-$0.82	-$0.12	N/A	-$0.39+71.5%	-$0.40+75.9%	-$1.20-114.2%	N/A
Diluted Shares (Avg)	36M	37M	29M	N/A	7M0.0%	7M0.0%	7M0.0%	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

MEIP Balance Sheet

MEIP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$18.3M-55.8%	$41.4M-65.8%	$120.8M-32.1%	$177.8M+2.1%	$174.1M-17.0%	$209.7M+153.7%	$82.7M-21.0%	$104.7M+87.9%	$55.7M+18.1%	$47.2M-27.2%	$64.8M+30.0%	$49.8M+36.3%	$36.5M+473.5%	$6.4M+52.9%	$4.2M
Current Assets	$18.3M-55.1%	$40.8M-62.1%	$107.5M-35.7%	$167.1M+1.4%	$164.8M-21.0%	$208.6M+153.8%	$82.2M-21.2%	$104.3M+88.6%	$55.3M+18.3%	$46.7M-27.3%	$64.3M+30.4%	$49.3M+36.8%	$36.0M+467.6%	$6.3M+53.7%	$4.1M
Cash & Equivalents	$18.0M+386.1%	$3.7M-78.1%	$16.9M+7.4%	$15.7M+84.2%	$8.5M-30.7%	$12.3M+28.6%	$9.6M-27.9%	$13.3M+57.4%	$8.5M-22.0%	$10.8M-42.1%	$18.7M+35.9%	$13.8M-61.3%	$35.6M+473.6%	$6.2M+60.8%	$3.9M
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M-83.8%	$8.4M-91.3%	$96.2M-23.3%	$125.4M+0.6%	$124.6M-6.1%	$132.7M+282.0%	$34.7M-35.9%	$54.2M+1013.8%	$4.9M-11.7%	$5.5M+11.2%	$5.0M+7.4%	$4.6M+175.6%	$1.7M-5.6%	$1.8M-25.3%	$2.4M
Current Liabilities	$1.4M-83.8%	$8.4M-58.9%	$20.3M-16.8%	$24.4M+20.9%	$20.2M+46.9%	$13.8M-3.8%	$14.3M+81.4%	$7.9M+62.0%	$4.9M-11.7%	$5.5M+11.2%	$5.0M+7.4%	$4.6M+175.6%	$1.7M-5.6%	$1.8M-25.3%	$2.4M
Non-Current Liabilities	$0	$0-100.0%	$75.8M-24.9%	$101.0M-3.3%	$104.4M-12.2%	$118.9M+482.0%	$20.4M-55.9%	$46.3M	$0	$0	$0	$0	$0	$0	$0
Total Equity	$16.9M-48.7%	$33.0M+34.1%	$24.6M-53.0%	$52.4M+6.0%	$49.5M-35.8%	$77.1M+60.8%	$47.9M-5.0%	$50.5M-0.7%	$50.8M+22.1%	$41.7M-30.3%	$59.8M+32.3%	$45.2M+29.6%	$34.9M+658.3%	$4.6M+156.4%	$1.8M
Retained Earnings	-$404.2M-4.1%	-$388.2M+4.4%	-$406.0M-8.5%	-$374.2M-17.0%	-$319.7M-14.8%	-$278.4M-20.4%	-$231.2M-7.8%	-$214.4M-23.0%	-$174.3M+1.5%	-$177.0M-13.4%	-$156.1M-26.5%	-$123.4M-28.2%	-$96.3M-13.1%	-$85.1M-9.7%	-$77.6M

Metric	Q3'2610-K	Q2'2610-Q	Q1'2610-K	Q4'2510-K	Q3'25	Q2'25	Q1'25	Q4'2410-K
Total Assets	$57.8M+178.1%	$82.9M+240.1%	$113.3M+308.4%	$18.3M-55.8%	$20.8M-70.8%	$24.4M-69.0%	$27.8M-72.6%	$41.4M-65.8%
Current Assets	$11.0M-47.2%	$10.9M-55.3%	$13.2M-52.3%	$18.3M-55.1%	$20.8M-65.0%	$24.4M-63.1%	$27.7M-68.6%	$40.8M-62.1%
Cash & Equivalents	$7.5M-63.1%	$8.8M-63.1%	$10.1M+45.5%	$18.0M+386.1%	$20.5M+764.5%	$23.7M+358.8%	$7.0M+106.2%	$3.7M-78.1%
Accounts Receivable	N/A	N/A	N/A	$0	$0	$0	$0	$0
Total Liabilities	$952K-23.1%	$1.1M-52.5%	$1.1M-62.8%	$1.4M-83.8%	$1.2M-93.9%	$2.3M-88.0%	$2.9M-85.6%	$8.4M-91.3%
Current Liabilities	$952K-23.1%	$1.1M-52.5%	$1.1M-62.8%	$1.4M-83.8%	$1.2M-87.1%	$2.3M-71.5%	$2.9M-66.5%	$8.4M-58.9%
Non-Current Liabilities	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%
Total Equity	$56.8M+190.9%	$81.8M+270.4%	$112.3M+351.3%	$16.9M-48.7%	$19.5M-61.7%	$22.1M-62.9%	$24.9M-69.4%	$33.0M+34.1%
Retained Earnings	-$462.3M-15.1%	-$438.6M-10.0%	-$407.8M-2.9%	-$404.2M-4.1%	-$401.5M-8.6%	-$398.9M-10.6%	-$396.2M-13.3%	-$388.2M+4.4%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.

MEIP Cash Flow Statement

MEIP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$10.4M	-$20.8M+58.7%	-$50.5M+3.8%	-$52.5M-7.7%	-$48.7M-52.5%	-$32.0M-193.3%	$34.3M+216.4%	-$29.4M-39.9%	-$21.0M-703.4%	$3.5M+119.5%	-$17.9M+36.4%	-$28.1M-44.3%	-$19.5M-93.7%	-$10.0M-41.8%	-$7.1M-8.9%	-$6.5M
Depreciation & Amortization	N/A	$368K-3.9%	$383K-0.8%	$386K+18.4%	$326K+14.4%	$285K+161.5%	$109K+36.3%	$80K+50.9%	$53K-37.6%	$85K+46.6%	$58K-9.4%	$64K+28.0%	$50K+11.1%	$45K+246.2%	$13K0.0%	$13K
Stock-Based Compensation	N/A	-$144K-106.3%	$2.3M-36.5%	$3.6M-57.0%	$8.3M-18.5%	$10.2M+50.6%	$6.8M+3.6%	$6.6M+104.0%	$3.2M+39.6%	$2.3M-15.4%	$2.7M-35.5%	$4.2M-11.0%	$4.7M+215.2%	$1.5M+194.7%	$511K+5.6%	$484K
Capital Expenditures	N/A	$0-100.0%	$7K-80.0%	$35K-92.7%	$479K-32.3%	$708K-20.8%	$894K+312.0%	$217K	N/A	$51K+1175.0%	$4K-73.3%	$15K-70.0%	$50K+31.6%	$38K	N/A	$48K
Free Cash Flow	N/A	-$20.8M+58.7%	-$50.5M+3.9%	-$52.5M-6.7%	-$49.2M-50.7%	-$32.7M-197.9%	$33.4M+212.6%	-$29.6M	N/A	$3.4M+119.2%	-$17.9M+36.4%	-$28.1M-44.0%	-$19.5M-93.4%	-$10.1M	N/A	-$6.5M
Investing Cash Flow	-$97.3M	$35.1M-28.5%	$49.1M-8.5%	$53.7M+679.0%	$6.9M-72.1%	$24.7M+123.2%	-$106.3M-537.1%	$24.3M+154.9%	-$44.3M-339.9%	-$10.1M-201.1%	$10.0M	N/A	N/A	-$38K	N/A	-$48K
Financing Cash Flow	$94.8M	$0+100.0%	-$11.9M-29570.0%	-$40K-100.1%	$49.1M+1314.4%	$3.5M-95.4%	$74.8M+5295.2%	$1.4M-98.0%	$70.2M+1567.0%	$4.2M	N/A	N/A	N/A	$39.5M+318.6%	$9.4M+585.0%	$1.4M
Dividends Paid	N/A	$0-100.0%	$11.7M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2610-K	Q2'2610-Q	Q1'2610-K	Q4'2510-K	Q3'25	Q2'25	Q1'25	Q4'2410-K
Operating Cash Flow	-$1.5M+53.5%	-$1.9M+47.4%	-$4.5M+60.6%	-$2.5M+86.3%	-$3.3M-11.6%	-$3.7M+66.8%	-$11.4M+38.1%	-$18.0M-59.3%
Depreciation & Amortization	N/A	N/A	$0-100.0%	N/A	N/A	N/A	$368K+323.0%	N/A
Stock-Based Compensation	N/A	N/A	$284K+310.4%	N/A	$16K-97.6%	-$103K-112.1%	-$135K-137.2%	N/A
Capital Expenditures	N/A	N/A	N/A	$0	$0	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	-$2.5M+86.3%	-$3.3M-11.6%	N/A	N/A	-$18.0M
Investing Cash Flow	$2.1M	$569K-97.2%	-$100.0M-780.4%	$0-100.0%	$0-100.0%	$20.5M-16.6%	$14.7M+196.5%	$19.5M+0.8%
Financing Cash Flow	-$1.8M	$5K	$96.6M	$0+100.0%	$0	$0+100.0%	$0	-$208K
Dividends Paid	N/A	N/A	N/A	$0	$0	N/A	N/A	$0
Share Buybacks	$1.8M	N/A	N/A	N/A	$0	N/A	N/A	N/A

MEIP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MEIP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	N/A	N/A	N/A	100.0%+4.0pp	96.0%+5.6pp	90.4%+77.1pp	13.3%	-108.6%	78.5%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	22.3%+97.6pp	-75.3%	-185.5%	-173.7%	-92.6%	-940.9%	-1762.4%	10.3%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	27.2%+92.8pp	-65.5%	-132.7%	-117.8%	-170.0%	-342.2%	-2470.3%	11.5%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-94.2%-148.0pp	53.8%+183.8pp	-130.0%-26.9pp	-103.0%-20.1pp	-82.9%-21.7pp	-61.2%-26.1pp	-35.1%+44.3pp	-79.4%-84.7pp	5.3%+55.3pp	-50.1%+4.6pp	-54.7%+5.4pp	-60.1%-28.0pp	-32.1%+131.5pp	-163.6%+214.4pp	-378.0%
Return on Assets	-87.2%-130.2pp	43.0%+69.5pp	-26.5%+3.9pp	-30.4%-6.8pp	-23.5%-1.1pp	-22.5%-2.1pp	-20.3%+17.9pp	-38.3%-43.1pp	4.8%+49.0pp	-44.2%+6.3pp	-50.5%+4.0pp	-54.5%-23.9pp	-30.6%+87.4pp	-118.0%+44.7pp	-162.7%
Current Ratio	13.50+8.6x	4.88-0.4x	5.29-1.6x	6.84-1.3x	8.15-7.0x	15.17+9.4x	5.75-7.5x	13.23+1.9x	11.37+2.9x	8.48-4.5x	12.96+2.3x	10.68-10.8x	21.51+17.9x	3.58+1.8x	1.74
Debt-to-Equity	0.08-0.2x	0.25-3.7x	3.91+1.5x	2.39-0.1x	2.52+0.8x	1.72+1.0x	0.72-0.3x	1.07+1.0x	0.100.0x	0.130.0x	0.080.0x	0.10+0.1x	0.05-0.3x	0.39-0.9x	1.32
Asset Turnover	0.00-1.6x	1.58+1.2x	0.40+0.2x	0.230.0x	0.20+0.1x	0.13+0.1x	0.060.0x	0.02-0.4x	0.42	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	-77.3%	-107.6%	-121.0%	-93.9%	120.2%	-603.0%	N/A	14.8%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2610-K	Q2'2610-Q	Q1'2610-K	Q4'2510-K	Q3'25	Q2'25	Q1'25	Q4'2410-K
Operating Margin	-40018.5%	-49778.3%	N/A	N/A	-1373.3%	-1236.9%	N/A	N/A
Net Margin	-43877.8%	-51331.7%	N/A	N/A	-1273.8%	-959.5%	N/A	N/A
Return on Equity	-41.7%-28.5pp	-37.6%-25.5pp	-3.2%+29.0pp	N/A	-13.2%+4.7pp	-12.1%+6.5pp	-32.2%-101.5pp	N/A
Return on Assets	-41.0%-28.6pp	-37.1%-26.2pp	-3.2%+25.6pp	N/A	-12.4%+0.4pp	-11.0%+3.1pp	-28.8%-84.5pp	N/A
Current Ratio	11.53-5.3x	10.04-0.6x	12.39+2.7x	13.50+8.6x	16.78+10.6x	10.66+2.4x	9.66-0.7x	4.88-0.4x
Debt-to-Equity	0.020.0x	0.01-0.1x	0.01-0.1x	0.08-0.2x	0.06-0.3x	0.10-0.2x	0.12-0.1x	0.25-3.7x
Asset Turnover	0.000.0x	0.000.0x	N/A	N/A	0.010.0x	0.010.0x	0.00-0.6x	N/A
FCF Margin	N/A	N/A	N/A	N/A	-1617.3%	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Mei Pharma Inc MEIP	FY2025	$0	-$15.9M	N/A	$100.8M	—
Tscan Therapeutics, Inc. TCRX	FY2025	$10.3M	-$129.8M	N/A	$23.4M	38/100
HilleVax, Inc. HLVX	FY2024	N/A	-$147.3M	N/A	$104.8M	—
Macrogenics Inc MGNX	FY2025	$149.5M	-$75K	-0.1%	$275.2M	56/100
Pliant Therapeutics, Inc. PLRX	FY2025	$0	$149.3M	N/A	$70.3M	—
Oramed Pharmaceuticals Inc ORMP	FY2025	$2.0M	$75K	3.8%	$207.2M	51/100

Where Mei Pharma Inc Ranks

Frequently Asked Questions

What is Mei Pharma Inc's annual revenue?

Mei Pharma Inc (MEIP) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Mei Pharma Inc's revenue growing?

Mei Pharma Inc (MEIP) revenue declined by 100.0% year-over-year, from $65.3M to $0 in fiscal year 2025.

Is Mei Pharma Inc profitable?

No, Mei Pharma Inc (MEIP) reported a net income of -$15.9M in fiscal year 2025.

What is Mei Pharma Inc's EBITDA?

Mei Pharma Inc (MEIP) had EBITDA of -$17.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Mei Pharma Inc's return on equity (ROE)?

Mei Pharma Inc (MEIP) has a return on equity of -94.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Mei Pharma Inc's free cash flow?

Mei Pharma Inc (MEIP) recorded an outflow of $20.8M in free cash flow during fiscal year 2025. This represents a 58.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Mei Pharma Inc's operating cash flow?

Mei Pharma Inc (MEIP) recorded an outflow of $20.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Mei Pharma Inc's total assets?

Mei Pharma Inc (MEIP) had $18.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Mei Pharma Inc's capital expenditures?

Mei Pharma Inc (MEIP) reported no capital expenditure during fiscal year 2025.

How much does Mei Pharma Inc spend on research and development?

Mei Pharma Inc (MEIP) invested $3.9M in research and development during fiscal year 2025.

How many shares does Mei Pharma Inc have outstanding?

Mei Pharma Inc (MEIP) had 7M shares outstanding as of fiscal year 2025.

What is Mei Pharma Inc's current ratio?

Mei Pharma Inc (MEIP) had a current ratio of 13.50 as of fiscal year 2025, which is generally considered healthy.

What is Mei Pharma Inc's debt-to-equity ratio?

Mei Pharma Inc (MEIP) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Mei Pharma Inc's return on assets (ROA)?

Mei Pharma Inc (MEIP) had a return on assets of -87.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Mei Pharma Inc's Altman Z-Score?

Mei Pharma Inc (MEIP) has an Altman Z-Score of 11.69, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Mei Pharma Inc's Piotroski F-Score?

Mei Pharma Inc (MEIP) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Mei Pharma Inc's earnings high quality?

Mei Pharma Inc (MEIP) reported a net loss of $15.9M while operations used $20.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.